NanoBio Corporation Announces Appointment of Dr. Ronald Cresswell to Board of Directors

|

ANN ARBOR, Mich., Oct. 11 /PRNewswire/ -- NanoBio® Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of serious infections, today announced that Ronald M. Cresswell, Ph.D., Hon. D. Sc., F.R.S.E., has been named to its Board of Directors. Dr. Cresswell is the former Senior Vice President and Chief Scientific Officer of Warner-Lambert, and has served on the Board of Directors of Esperion Therapeutics, Inc., Allergan, Inc., Curagen Corporation, and Vasogen, Inc.

"Dr. Cresswell brings decades of experience working with some of the world's most respected pharmaceutical and health care companies," stated James R. Baker, Jr., M.D., Chairman of the Board of NanoBio Corporation. "His addition to the NanoBio Board adds significant value at this important juncture for the company as we move forward with several promising product development programs that represent significant commercial opportunities."

Dr. Ronald Cresswell brings over 30 years of research and commercial development experience in various therapeutic areas to NanoBio. Dr. Cresswell began his tenure with Warner-Lambert in 1988 as the President of Research and Development of the Parke-Davis Pharmaceutical Research Division. From 1989- 1998, he served as Vice President and Chairman of the Parke-Davis Worldwide Pharmaceutical Research Division. Dr. Cresswell's vision and leadership in the development of Lipitor® at Parke-Davis was instrumental in the product's ultimate success. Dr. Cresswell joined Warner-Lambert from Laporte Industries, Ltd., an international chemical company, where he was Chief Operating Officer. Prior to this, Dr. Cresswell was with Burroughs Wellcome for over 20 years. At Burroughs Wellcome, he held a broad range of research and development positions in both the United Kingdom and the United States, and was responsible for a research staff of over 3,000 people.

In addition to Dr. Baker and Dr. Cresswell, other members of NanoBio Corporation's Board of Directors include Norman C. Selby, Senior Managing Director of Perseus L.L.C.; Dr. Robert C. Moellering, Jr., the Shields Warren- Mallinckrodt Professor of Medical Research at Harvard Medical School; and Michael J. Nestor, NanoBio's President and Chief Executive Officer.

About NanoBio Corporation

NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), methicillin resistant Staphylococcus aureus (MRSA), and a mucosal vaccine for influenza. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.